LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Inicio・Lista de Acciones・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Cerrado

SectorSanidad

572.1 0.14

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

569.02

Máximo

574.61

Métricas clave
By Trading Economics
Ingresos	-72M -114M
Ventas	74M 287M
BPA	-4.956
Margen de beneficios	-39.75
Empleados	528
EBITDA	-75M -114M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+0.05% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	3.7B 13B
Apertura anterior	571.96
Cierre anterior	572.1

Noticias sobre sentimiento de mercado

By Acuity

23%

77%

43 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

263.2 / 277.1 Soporte y Resistencia

Madrigal Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 dic 2025, 22:53 UTC

Adquisiciones, fusiones, absorciones

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13 dic 2025, 00:04 UTC

Adquisiciones, fusiones, absorciones

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14 dic 2025, 23:46 UTC

Charlas de Mercado

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14 dic 2025, 23:36 UTC

Charlas de Mercado

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14 dic 2025, 22:38 UTC

Adquisiciones, fusiones, absorciones

Fortescue to Take Full Control of US$101M Copper Miner Alta

14 dic 2025, 22:02 UTC

Adquisiciones, fusiones, absorciones

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14 dic 2025, 22:01 UTC

Adquisiciones, fusiones, absorciones

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14 dic 2025, 22:01 UTC

Adquisiciones, fusiones, absorciones

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14 dic 2025, 22:00 UTC

Adquisiciones, fusiones, absorciones

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14 dic 2025, 22:00 UTC

Adquisiciones, fusiones, absorciones

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14 dic 2025, 21:59 UTC

Adquisiciones, fusiones, absorciones

Fortescue to Acquire Remaining 64% of Alta Copper

14 dic 2025, 17:00 UTC

Ganancias

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14 dic 2025, 08:30 UTC

Adquisiciones, fusiones, absorciones

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13 dic 2025, 16:48 UTC

Adquisiciones, fusiones, absorciones

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dic 2025, 08:00 UTC

Adquisiciones, fusiones, absorciones

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dic 2025, 07:00 UTC

Adquisiciones, fusiones, absorciones

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 dic 2025, 00:24 UTC

Adquisiciones, fusiones, absorciones

Want a Piece Of SpaceX? -- Barrons.com

12 dic 2025, 23:49 UTC

Adquisiciones, fusiones, absorciones

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 dic 2025, 22:52 UTC

Charlas de Mercado

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 dic 2025, 22:32 UTC

Ganancias

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 dic 2025, 20:45 UTC

Ganancias

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 dic 2025, 20:41 UTC

Charlas de Mercado

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 dic 2025, 20:20 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 dic 2025, 19:23 UTC

Ganancias

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 dic 2025, 18:35 UTC

Adquisiciones, fusiones, absorciones

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 dic 2025, 18:33 UTC

Adquisiciones, fusiones, absorciones

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 dic 2025, 18:31 UTC

Charlas de Mercado

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 dic 2025, 17:49 UTC

Ganancias

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 dic 2025, 17:34 UTC

Adquisiciones, fusiones, absorciones

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Comparación entre iguales

Cambio de precio

Madrigal Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

0.05% repunte

Estimación a 12 Meses

Media 571.73 USD 0.05%

Máximo 670 USD

Mínimo 445 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Madrigal Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para Madrigal Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

263.2 / 277.1Soporte y Resistencia

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

43 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.